Known targets — ChEMBL curated mechanism
ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4
The experimentally established mechanism targets of Camptothecin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 18/20 | 0.90 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.90 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.90 |
| ▸ | MEN1 | O00255 | 4/20 | 0.90 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.90 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.90 |
| ▸ | GLA | P06280 | 3/20 | 0.90 |
| ▸ | TP53 | P04637 | 2/20 | 0.90 |
| ▸ | HPGD | P15428 | 2/20 | 0.90 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.90 |
| ▸ | HBB | P68871 | 2/20 | 0.90 |
| ▸ | RAB9A | P51151 | 2/20 | 0.90 |
| ▸ | BLM | P54132 | 2/20 | 0.90 |
| ▸ | STAT6 | P42226 | 1/20 | 0.90 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.90 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.90 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.90 |
| ▸ | GMNN | O75496 | 1/20 | 0.90 |
| ▸ | LMNA | P02545 | 1/20 | 0.90 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Camptothecin SCHEMBL1618774 | 0.96 | TOP1 (0.91) | TOP1ALDH1A1KDM4EMEN1KMT2A | |
| Camptothecin SCHEMBL5967412 | 0.96 | TOP1 (0.95) | TOP1ALDH1A1KDM4EMEN1KMT2A | |
| Camptothecin SCHEMBL2864815 | 0.95 | TOP1 (0.93) | TOP1ALDH1A1KDM4EMEN1KMT2A | |
| Camptothecin SCHEMBL6038 | 0.95 | TOP1 (1.00) | TOP1ALDH1A1KDM4EMEN1KMT2A | |
| Camptothecin SCHEMBL29369924 | 0.95 | TOP1 (1.00) | TOP1ALDH1A1KDM4EMEN1KMT2A | |
| Camptothecin SCHEMBL29351099 | 0.95 | TOP1 (1.00) | TOP1ALDH1A1KDM4EMEN1KMT2A | |
| Camptothecin SCHEMBL4304557 | 0.95 | TOP1 (1.00) | TOP1ALDH1A1KDM4EMEN1KMT2A | |
| Camptothecin SCHEMBL2298909 | 0.95 | TOP1 (1.00) | TOP1ALDH1A1KDM4EMEN1KMT2A | |
| Camptothecin SCHEMBL788063 | 0.95 | TOP1 (1.00) | TOP1ALDH1A1KDM4EMEN1KMT2A | |
| Camptothecin SCHEMBL29360250 | 0.95 | TOP1 (1.00) | TOP1ALDH1A1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116178474-A | Camptothecin modified cholesterol and preparation method and application thereof | 湖南省中医药研究院 | 2023-05-30 | — | — | CN | claimed |
| CN-115317623-A | Camptothecin modified collagen and preparation method and application thereof | 湖南工商大学 | 2022-11-11 | — | — | CN | claimed |
| CN-116178474-A | Camptothecin modified cholesterol and preparation method and application thereof | 湖南省中医药研究院 | 2023-05-30 | — | — | CN | disclosed |
| CN-115317623-A | Camptothecin modified collagen and preparation method and application thereof | 湖南工商大学 | 2022-11-11 | — | — | CN | disclosed |
| US-7157433-B2 | Compounds, compositions as carriers for steroid/nonsteroid anti-inflammatory; antienoplastic and antiviral active molecules | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB (HR) | 2007-01-02 | — | — | US | disclosed |
| EP-1551865-A2 | HYBRID MOLCULES OF MACROLIDES WITH STEROID/NON-STEROID ANTI-INFLAMMATORY, ANTINEOPLASTIC AND ANTIVIRAL ACTIVE MOLECULES | Pliva - Istrazivacki Institut d.o.o. (HR) | 2005-07-13 | — | — | EP | disclosed |
| US-20040077612-A1 | Novel compounds, compositions as carriers for steroid/nonsteroid anti-inflammatory; antienoplastic and antiviral active molecules | PLIVA DD (HR) | 2004-04-22 | — | — | US | disclosed |
| WO-2004005313-A2 | HYBRID MOLECULES OF MACROLIDES WITH STEROID/NON-STEROID ANTI-INFLAMMATORY, ANTINEOPLASTIC AND ANTIVIRAL ACTIVE MOLECULES | PLIVA - ISTRAZIVACKI INSTITUT D.O.O. (US) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077612-A1 | Novel compounds, compositions as carriers for steroid/nonsteroid anti-inflammatory; antienoplastic and antiviral active molecules | MALT1, TNF, IL1B | TOP1 607/4885ALDH1A1 2316/4885KDM4E 2444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.